BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 25598973)

  • 1. CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy.
    Moertel CL; Xia J; LaRue R; Waldron NN; Andersen BM; Prins RM; Okada H; Donson AM; Foreman NK; Hunt MA; Pennell CA; Olin MR
    J Immunother Cancer; 2014; 2(1):46. PubMed ID: 25598973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
    Choueiry F; Torok M; Shakya R; Agrawal K; Deems A; Benner B; Hinton A; Shaffer J; Blaser BW; Noonan AM; Williams TM; Dillhoff M; Conwell DL; Hart PA; Cruz-Monserrate Z; Bai XF; Carson WE; Mace TA
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD200-CD200R Pathway in the Regulation of Tumor Immune Microenvironment and Immunotherapy.
    Liu JQ; Hu A; Zhu J; Yu J; Talebian F; Bai XF
    Adv Exp Med Biol; 2020; 1223():155-165. PubMed ID: 32030689
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD200 Blockade Modulates Tumor Immune Microenvironment but Fails to Show Efficacy in Inhibiting Tumor Growth in a Murine Model of Melanoma.
    Talebian F; Yu J; Lynch K; Liu JQ; Carson WE; Bai XF
    Front Cell Dev Biol; 2021; 9():739816. PubMed ID: 34692697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD200/CD200R: Bidirectional Role in Cancer Progression and Immunotherapy.
    Nip C; Wang L; Liu C
    Biomedicines; 2023 Dec; 11(12):. PubMed ID: 38137547
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancel cancer: The immunotherapeutic potential of CD200/CD200R blockade.
    Choe D; Choi D
    Front Oncol; 2023; 13():1088038. PubMed ID: 36756156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-derived vaccines containing CD200 inhibit immune activation: implications for immunotherapy.
    Xiong Z; Ampudia-Mesias E; Shaver R; Horbinski CM; Moertel CL; Olin MR
    Immunotherapy; 2016 Sep; 8(9):1059-71. PubMed ID: 27485078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upregulation of CD200 is associated with Foxp3+ regulatory T cell expansion and disease progression in acute myeloid leukemia.
    Memarian A; Nourizadeh M; Masoumi F; Tabrizi M; Emami AH; Alimoghaddam K; Hadjati J; Mirahmadian M; Jeddi-Tehrani M
    Tumour Biol; 2013 Feb; 34(1):531-42. PubMed ID: 23179394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CD200-CD200R Axis Promotes Squamous Cell Carcinoma Metastasis via Regulation of Cathepsin K.
    Khan IZ; Del Guzzo CA; Shao A; Cho J; Du R; Cohen AO; Owens DM
    Cancer Res; 2021 Oct; 81(19):5021-5032. PubMed ID: 34183355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions.
    Koning N; Swaab DF; Hoek RM; Huitinga I
    J Neuropathol Exp Neurol; 2009 Feb; 68(2):159-67. PubMed ID: 19151626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD200-CD200R signaling suppresses anti-tumor responses independently of CD200 expression on the tumor.
    Rygiel TP; Karnam G; Goverse G; van der Marel AP; Greuter MJ; van Schaarenburg RA; Visser WF; Brenkman AB; Molenaar R; Hoek RM; Mebius RE; Meyaard L
    Oncogene; 2012 Jun; 31(24):2979-88. PubMed ID: 22020332
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD200 Checkpoint Reversal: A Novel Approach to Immunotherapy.
    Xiong Z; Ampudia Mesias E; Pluhar GE; Rathe SK; Largaespada DA; Sham YY; Moertel CL; Olin MR
    Clin Cancer Res; 2020 Jan; 26(1):232-241. PubMed ID: 31624103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The pro-tumor effect of CD200 expression is not mimicked by agonistic CD200R antibodies.
    Pilch Z; Tonecka K; Skorzynski M; Sas Z; Braniewska A; Kryczka T; Boon L; Golab J; Meyaard L; Rygiel TP
    PLoS One; 2019; 14(1):e0210796. PubMed ID: 30653571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Merkel cell carcinoma expresses the immunoregulatory ligand CD200 and induces immunosuppressive macrophages and regulatory T cells.
    Gaiser MR; Weis CA; Gaiser T; Jiang H; Buder-Bakhaya K; Herpel E; Warth A; Xiao Y; Miao L; Brownell I
    Oncoimmunology; 2018; 7(5):e1426517. PubMed ID: 29721394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions.
    Talebian F; Liu JQ; Liu Z; Khattabi M; He Y; Ganju R; Bai XF
    PLoS One; 2012; 7(2):e31442. PubMed ID: 22319630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative Assessment of CD200 and CD200R Expression in Lung Cancer.
    Vathiotis IA; MacNeil T; Zugazagoitia J; Syrigos KN; Aung TN; Gruver AM; Vaillancourt P; Hughes I; Hinton S; Driscoll K; Rimm DL
    Cancers (Basel); 2021 Mar; 13(5):. PubMed ID: 33804482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Elafin and CD200 as Immune Checkpoint Molecules Involved in Celiac Disease.
    Ponce-de-León C; Lorite P; López-Casado MÁ; Mora P; Palomeque T; Torres MI
    Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38255930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD200R, a co-inhibitory receptor on immune cells, predicts the prognosis of human hepatocellular carcinoma.
    Sun H; Xu J; Huang M; Huang Q; Sun R; Xiao W; Sun C
    Immunol Lett; 2016 Oct; 178():105-13. PubMed ID: 27562325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD200R signaling in tumor tolerance and inflammation: A tricky balance.
    Rygiel TP; Meyaard L
    Curr Opin Immunol; 2012 Apr; 24(2):233-8. PubMed ID: 22264927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination CD200R/PD-1 blockade in a humanised mouse model.
    Fellermeyer M; Anzilotti C; Paluch C; Cornall RJ; Davis SJ; Gileadi U
    Immunother Adv; 2023; 3(1):ltad006. PubMed ID: 37082107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.